Aquestive Therapeutics, Inc. (AQST)

Market Cap	512.59M +89.9%
Revenue (ttm)	44.55M -22.6%
Net Income	-83.78M
EPS	-0.78
Shares Out	122.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,360,018
Open	4.190
Previous Close	4.290
Day's Range	4.170 - 4.366
52-Week Range	2.120 - 7.550
Beta	1.59
Analysts	Strong Buy
Price Target	9.00 (+114.29%)
Earnings Date	Mar 4, 2026

About AQST

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 25, 2018
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: AQST
• Website: https://www.aquestive.com

Financial Performance

In 2025, Aquestive Therapeutics's revenue was $44.55 million, a decrease of -22.61% compared to the previous year's $57.56 million. Losses were -$83.78 million, 89.8% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price target is $9.0, which is an increase of 114.29% from the latest price.

Price Target

$9.0

(114.29% upside)

Analyst Consensus: Strong Buy